Jonathan E. Lim - 08 Jun 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Reporting relationship: Director
Issuer ticker: MAZE
Reported as of: 08 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 16:28:22 UTC
Prior SEC filing: 30 Jan 2026
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Courtney Phillips, as attorney-in-fact

Key filing fact

Jonathan E. Lim filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 10 Jun 2026.

Key facts

This page summarizes Jonathan E. Lim's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2026, 16:28.

Change

Previous filing in this sequence was filed on 30 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001283290 Primary reporting owner

Lim Jonathan E

Relationship: Director
Address: C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Signature: /s/ Courtney Phillips, as attorney-in-fact
Signature date: 10 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +18,000
Change %
Price: $0.000000^*
Shares after: 18,000
Date: 08 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,000
Exercise price: $23.58
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.